A Prospective International Study on Safety and Efficacy of Hypofractionated Radiation Therapy for Post-Operative Breast Cancer Patients in Asian Countries

Karasawa, Kumiko; Kono, S.; Banu, Ameena; Dung, To Anh; Адылханов, Т А; Erdentuya, Y.; Zhou, Jun; Calaguas, M.J.; Erawati, Dyah; Thephamongkhol, Kullathorn; Jang, Won Il

doi:10.1016/j.ijrobp.2018.07.1595

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For advanced toxicity, grade-2 pulmonary toxicity was obtained in 1 patient, grade-2 skin toxicity in 1 patient, and grade-2 subcutaneous toxicity in 1 patient. During that observation follow-up, they also found 1 locoregional recurrence, 3 distant metastases, and 2 cases of death related to breast cancer [14].…”

Section: Discussionmentioning

confidence: 89%

Acute and Late Toxicity In Breast Cancer Patient That Received Hypofractionated Adjuvant Radiotherapy after Breast Conserving Surgery: A Case Report

Dewi

Kodrat

2020

Indonesian Journal of Cancer

View full text Add to dashboard Cite

Introduction: Breast cancer is the most common female malignancy worldwide. Breastconserving surgery followed by adjuvant radiotherapy is a preferable treatment option. Hypofractionated radiotherapy is an attractive fractionation scheme because of its shorter treatment duration. This paper aims to report the short-term and long-term toxicity of hypofractionated radiotherapy in breast cancer patients at our institution. Case Presentation: A 58-year-old woman with right breast cancer T2N1M0 had undergone breast-conserving surgery with axilla lymph node dissection. This patient underwent adjuvant whole breast radiotherapy with a dose of 42.56 Gy in 16 fractions followed by tumor bed boost with a dose of 16 Gy in 8 fractions. After undergoing the fourth fraction of boost, she had hyperpigmentation on her radiation area (RTOG skin toxicity grade 1). At the 6-month follow-up, the hyperpigmentation still appeared. Until the 24-month follow-up, after she completed radiotherapy, there was no sign of tumor recurrence and toxicity.Conclusion: Hypofractionated radiotherapy could be an option for breast cancer treatment that provides equivalent local control, survival, and side effects to conventional fractionation radiotherapy.

show abstract

Section: Discussionmentioning

confidence: 89%

Acute and Late Toxicity In Breast Cancer Patient That Received Hypofractionated Adjuvant Radiotherapy after Breast Conserving Surgery: A Case Report

Dewi

Kodrat

2020

Indonesian Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Also, the initial results of a prospective international study of hypofractionated PMRT in Asian countries show the effectiveness and safety of hypofractionated PMRT (and hypofractionated whole breast irradiation) to be similar to conventional fractionation. 43 All the Asian experts agreed with and accepted completely [A ¼ 100%] the 'recommendation 6.1.2.6a' (above and Table 2), with the addition of the text 'depending on local reimbursement practices and equipment availability'. Table S1, available at Annals of Oncology online and Table 2).…”

Section: Recommendation 6: Treatmentmentioning

confidence: 89%

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

Park

Senkus-Konefka

et al. 2020

Annals of Oncology

View full text Add to dashboard Cite

In view of the planned new edition of the most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of primary breast cancer published in 2015, it was decided at the ESMO Asia Meeting in November 2018, by both the ESMO and the Korean Society of Medical Oncology (KSMO), to convene a special face-to-face guidelines meeting in 2019 in Seoul. The aim was to adapt the latest ESMO 2019 guidelines to take into account the ethnic and geographical differences associated with the treatment of early breast cancer in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with early breast cancer representing the oncology societies of Korea (KSMO), China (CSCO), India (ISMPO) Japan (JSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence, and was independent of both the current treatment practices, and the drug availability and reimbursement situations, in the individual participating Asian countries.

show abstract

A Prospective International Study on Safety and Efficacy of Hypofractionated Radiation Therapy for Post-Operative Breast Cancer Patients in Asian Countries

Cited by 2 publications

References 0 publications

Acute and Late Toxicity In Breast Cancer Patient That Received Hypofractionated Adjuvant Radiotherapy after Breast Conserving Surgery: A Case Report

Acute and Late Toxicity In Breast Cancer Patient That Received Hypofractionated Adjuvant Radiotherapy after Breast Conserving Surgery: A Case Report

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

Contact Info

Product

Resources

About